Actimab-A, a CD33-targeted Actinium-225 radioconjugate, drives potent mutation-agnostic efficacy in AML models. // Blood Neoplasia. – URL: https://www.sciencedirect.com/science/article/pii/S2950328026001470?dgcid=rss_sd_all
Actimab-A, a CD33-targeted Actinium-225 radioconjugate, drives potent mutation-agnostic efficacy in AML models. Blood Neoplasia. https://www.sciencedirect.com/science/article/pii/S2950328026001470?dgcid=rss_sd_all
“Actimab-A, a CD33-targeted Actinium-225 radioconjugate, drives potent mutation-agnostic efficacy in AML models.” Blood Neoplasia.
@article{article38344,
title = {Actimab-A, a CD33-targeted Actinium-225 radioconjugate, drives potent mutation-agnostic efficacy in AML models},
journal = {Blood Neoplasia},
url = {https://www.sciencedirect.com/science/article/pii/S2950328026001470?dgcid=rss_sd_all}
}